Interv Akut Kardiol. 2023;22(3):136-137 | DOI: 10.36290/kar.2023.027

Complex intervention with intravenous P2Y12 inhibitor

Vojtěch Brázdil1, 2, Martin Hudec1, 2, Martin Poloczek1
1 Interní kardiologická klinika FN Brno
2 Lékařská fakulta Masarykovy univerzity, Brno

Kangrelor represents the only intravenous inhibitor of the platelet receptor P2Y12 with clinically proven effectiveness in reducing ischemic complications of percutaneous coronary intervention (PCI). According to the Summary of Product Characteristics (SPC), Kangrelor is recommended for patients undergoing PCI who have not been treated with an oral P2Y12 inhibitor or for whom this therapy is not possible or suitable. In the following case study, a high-risk patient undergoing a complex interventional procedure using this preparation will be presented (1).

Keywords: kangrelor, Kengrexal®, intravenous P2Y12 inhibitor, Shockwave.

Received: May 15, 2023; Revised: July 3, 2023; Accepted: October 18, 2023; Published: November 7, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brázdil V, Hudec M, Poloczek M. Complex intervention with intravenous P2Y12 inhibitor. Interv Akut Kardiol. 2023;22(3):136-137. doi: 10.36290/kar.2023.027.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. J Am Heart Assoc. 2021 Jul 6;10(13):e022125. doi: 10.1161/JAHA.121.022125. Epub 2021 Jul 2. PMID: 34212768; PMCID: PMC8403274. Go to original source... Go to PubMed...
    2. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient­‑level data. Lancet 2013;382:1981-92. Go to original source... Go to PubMed...
    3. Prüller F, Bis L, Milke OL, et al. Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients. J Clin Med. 2018 Nov 15;7(11):442. doi: 10.3390/jcm7110442. PMID: 30445678; PMCID: PMC6262477. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.